Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | loss |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | FBXW7 loss indicates loss of the Fbxw7 gene, mRNA, and protein. |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 loss |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 loss | colon cancer | sensitive | Sirolimus | Preclinical | Actionable | In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291) | 23558291 |
FBXW7 loss | colon cancer | predicted - resistant | unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, an FBXW7-deficient colon cancer cell line in a mouse model was resistant to treatment with an unspecified PD-1 antibody, demonstrating poor survival and decreased inhibition of tumor growth compared to models with wild-type FBXW7 (PMID: 32371478). | 32371478 |
FBXW7 loss | melanoma | predicted - resistant | unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, an FBXW7-deficient melanoma cell line in a mouse model was resistant to treatment with an unspecified PD-1 antibody, demonstrating increased tumor volume and poor survival compared to models with wild-type FBXW7 (PMID: 32371478). | 32371478 |